Bio-Rad Laboratories
US life-science products company (NYSE: BIO, est. 1952) — Nuvia mixed-mode and ion-exchange chromatography resins, NGC FPLC systems, CHT Ceramic Hydroxyapatite for mAb polishing; broad diagnostics and life-science research portfolio alongside biopharma purification business.
- Country
- United States
- Revenue
- $2.8B
- Employees
- ~7,800 emp
ISO 9001
FDA GMP
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
| downstream-purification | ✓ | ✓ | — | ✓ |
| monitoring-conservation | ✓ | ✓ | — | ✓ |
Regulatorsepaadememoa-chinafdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Downstream Purification & Bioseparation | downstream-purification | Low | → |
| Invasive-species biomonitoring via eDNA | monitoring-conservation | Low | → |
| Wastewater-based epidemiology | diagnostics-medtech | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.